ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

SUMM Summit Therapeutics Plc

20.50
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Summit Therapeutics Plc LSE:SUMM London Ordinary Share GB00BN40HZ01 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 20.50 18.00 23.00 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Summit Therapeutics plc Summit's Pipeline Expands With Series Of New Mechanism Antibiotics Targeting Enterobacteriaceae

03/04/2019 12:00pm

UK Regulatory


 
TIDMSUMM 
 
   Summit Therapeutics plc 
 
   ('Summit' or the 'Company') 
 
   Summit's Pipeline Expands with Series of New Mechanism Antibiotics 
Targeting Enterobacteriaceae 
 
 
   -- Data to be Presented in Oral Session at ECCMID 2019 
 
 
   Oxford, UK, and Cambridge, MA, US, 3 April 2019 -- Summit Therapeutics 
plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic 
innovation, today announces the expansion of its pipeline with a series 
of new mechanism antibiotics, DDS-04, which targets Enterobacteriaceae. 
Key data from this series will be presented in an oral session at the 
29(th) European Congress of Clinical Microbiology & Infectious Diseases 
('ECCMID'), taking place 13-16 April 2019 in Amsterdam. 
 
   "The DDS-04 series provides us with a major opportunity to improve 
patient outcomes across several body sites where Enterobacteriaceae 
cause infection," said Dr David Roblin, President of R&D of Summit. "We 
look forward to developing the programme to show compelling clinical and 
economic data that offer significant advantages over standard of care 
for the patients in need." 
 
   Summit's DDS-04 series of new mechanism antibiotic compounds acts 
specifically on Enterobacteriaceae via LolCDE, an unexploited bacterial 
target. It is the first project to emerge from the Company's ESKAPE 
pathogen programme. Enterobacteriaceae are a family of Gram-negative 
bacteria, which include the critical threats Klebsiella pneumoniae and 
Escherichia coli. These bacteria are responsible for a large number of 
severe and often deadly infections of the bloodstream, lungs and urinary 
tract. The DDS-04 series has shown activity across a global panel of K. 
pneumoniae and E. coli strains, including strains resistant to current 
standard of care treatments. 
 
   Details of the presentation are as follows: 
 
   Date: 14 April 2019 
 
   Time: 1:42pm CEST 
 
   Session: Novel antimicrobial agents and discovery strategies 
 
   Location: Hall M 
 
   Title: Novel Small-Molecule Inhibitors of Bacterial Lipoprotein 
Transport with Potent Antimicrobial Activity against Enterobacteriaceae 
https://www.globenewswire.com/Tracker?data=HFcHzhpbNVsXZKQDxEeIUFq23t9hUrAybdjmN4JgK5WrYh2KSRaZMP3ykFqthYkSzvwzvY2II3vnpWSCEXFqZLtG-0BJ5g-ZeA1MTvbfGbfVmgugA_7wiWhwqIrHR7TPjZIFbSQVTKGEMKFtv21nNwExzdRiFxijDmFk804wG2o1A-vEmt_I9QrU1PyLo_AvXJkEPxCsXSCPpDnPnnarKMGjYO9zqRNH-jlHtLOqqileVu8l1Cgae2WDmC6GKF_w1OyPz1nu-5-rpOnFxHN0t5APHt3FyxGuXeK6-t6XS85HlksF4N1cOiYBsNc1yvw1k43KUuiAwGm0g7Pa-EgyHp88HM376LHLZD6R4Ba-3IpBlamT0oVpCWIFAaCdxbxKrh8Perp6y9aZcjN7XCrqDN4ybOswvj0bOMmAno2Lf2-Zd01nR3Kqs_BBOzJfYD8OUPQq0sdrpcPdM_075GmnVkICLQuBNZbbbxJSwdjUo-g= 
 
 
   Authors: E. Breidenstein, O. Abdulle, T. Avis, C. Charrier, C. Ciardullo, 
C. Coward, T. Duffy, N. Khan, C. Mason, P. Meo and D. Powell 
 
   About Enterobacteriaceae 
 
   Enterobacteriaceae are a family of Gram-negative bacteria responsible 
for a large number of severe and often deadly infections of the 
bloodstream, lungs and urinary tract. Increasing resistance of 
Enterobacteriaceae has rendered many marketed antibiotics ineffective 
against these bacteria. Two of the most alarming antibiotic resistance 
trends are extended-spectrum beta-lactamase (ESBL)-producing 
Enterobacteriaceae and carbapenem-resistant Enterobacteriaceae (CRE). 
ESBL is an enzyme that allows bacteria to become resistant to a wide 
variety of penicillin and cephalosporin antibiotics. ESBL-producing 
Enterobacteriaceae account for an estimated 26,000 infections annually 
in the US with 1,700 deaths, according to the US Centers for Drug 
Control and Prevention ('CDC'). CRE are resistant to nearly all existing 
antibiotics, including carbapenems which are considered the antibiotics 
of last resort. CRE account for an estimated 9,000 infections per year 
in the US and 600 deaths, according to the CDC. 
 
   About Summit Therapeutics 
 
   Summit Therapeutics is a leader in antibiotic innovation. Our new 
mechanism antibiotics are designed to become the new standards of care 
for the benefit of patients and create value for payors and healthcare 
providers. We are currently developing new mechanism antibiotics for 
infections caused by C. difficile, N. gonorrhoeae and ESKAPE pathogens. 
We are using our proprietary Discuva Platform to expand our pipeline. 
For more information, visit www.summitplc.com and follow us on Twitter 
@summitplc. 
 
   This announcement contains inside information for the purposes of 
Article 7 of EU Regulation 596/2014 (MAR). 
 
   Contacts 
 
 
 
 
Summit 
Glyn Edwards / Richard Pye (UK office)     Tel:                  44 (0)1235 443 951 
Michelle Avery (US office)                                          +1 617 225 4455 
 
Cairn Financial Advisers LLP (Nominated 
 Adviser)                                  Tel:                 +44 (0)20 7213 0880 
Liam Murray / Tony Rawlinson 
 
N+1 Singer (Joint Broker)                  Tel:                 +44 (0)20 7496 3000 
Aubrey Powell / Jen Boorer, Corporate 
 Finance 
 Tom Salvesen, Corporate Broking 
 
Bryan Garnier & Co Limited (Joint Broker)  Tel:                 +44 (0)20 7332 2500 
Phil Walker / Dominic Wilson 
MSL Group (US)                             Tel:                     +1 781 684 6557 
                                                         mailto:summit@mslgroup.com 
Jon Siegal                                                      summit@mslgroup.com 
                                                  --------------------------------- 
 
Consilium Strategic Communications (UK)    Tel:                 +44 (0)20 3709 5700 
Mary-Jane Elliott / Sue Stuart / Jessica          mailto:summit@consilium-comms.com 
 Hodgson /                                         summit@consilium-comms.com 
                                                  --------------------------------- 
Lindsey Neville 
 
 
   Summit Forward-looking Statements 
 
   Any statements in this press release about the Company's future 
expectations, plans and prospects, including but not limited to, 
statements about the clinical and preclinical development of the 
Company's product candidates, the therapeutic potential of the Company's 
product candidates, the potential commercialisation of the Company's 
product candidates, the sufficiency of the Company's cash resources, the 
timing of initiation, completion and availability of data from clinical 
trials, the potential submission of applications for marketing approvals 
and other statements containing the words "anticipate," "believe," 
"continue," "could," "estimate," "expect," "intend," "may," "plan," 
"potential," "predict," "project," "should," "target," "would," and 
similar expressions, constitute forward-looking statements within the 
meaning of The Private Securities Litigation Reform Act of 1995. Actual 
results may differ materially from those indicated by such 
forward-looking statements as a result of various important factors, 
including: the uncertainties inherent in the initiation of future 
clinical trials, availability and timing of data from ongoing and future 
clinical trials and the results of such trials, whether preliminary 
results from a clinical trial will be predictive of the final results of 
that trial or whether results of early clinical trials or preclinical 
studies will be indicative of the results of later clinical trials, 
expectations for regulatory approvals, laws and regulations affecting 
government contracts and funding awards, availability of funding 
sufficient for the Company's foreseeable and unforeseeable operating 
expenses and capital expenditure requirements and other factors 
discussed in the "Risk Factors" section of filings that the Company 
makes with the Securities and Exchange Commission, including the 
Company's Annual Report on Form 20-F for the fiscal year ended 31 
January 2018. Accordingly, readers should not place undue reliance on 
forward-looking statements or information. In addition, any 
forward-looking statements included in this press release represent the 
Company's views only as of the date of this release and should not be 
relied upon as representing the Company's views as of any subsequent 
date. The Company specifically disclaims any obligation to update any 
forward-looking statements included in this press release. 
 
   -END- 
 
 
 
 

(END) Dow Jones Newswires

April 03, 2019 07:00 ET (11:00 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

1 Year Summit Therapeutics Chart

1 Year Summit Therapeutics Chart

1 Month Summit Therapeutics Chart

1 Month Summit Therapeutics Chart

Your Recent History

Delayed Upgrade Clock